Virbac Grows Companion Animal 10% in the Same Half That Flattened Boehringer
Virbac grew H1 2026 revenue 7.4% to €768 million, with companion animal up 10% and North America up 10.1%, and now targets the top of its guidance range. In the same half, Boehringer's animal health sales went nearly flat. The divergence shows chronic-care mix, not market beta, is deciding who grows through the vet-traffic slump.
Virbac reported first-half 2026 revenue of €768 million on Monday, up 7.4% at constant rates and scope, and told investors to now target the top of its 5.5% to 7.5% organic growth range for the year. Companion animal revenue grew 10% in the same six months that produced a nearly flat animal health half at Boehringer Ingelheim. Set the two results side by side and the operator lesson is plain: soft clinic traffic is not hitting every portfolio equally, and product mix is deciding who grows.
The half delivered €768 million, with the specialty platforms growing at nearly twice the company rate
Virbac's first half came in at €768 million, up 7.4% at constant exchange rates and scope but 4.0% as reported, with currency absorbing the difference. The second quarter alone contributed €384 million, up 7.2% organically. Companion animal grew 10.0% while farm animal grew 6.7%, and every region participated: North America led at 10.1%, ahead of International at 7.5% and Europe at 6.5%.
The growth is concentrated where the company has aimed it. Virbac's "Supercharge" platforms, its priority categories spanning petfood, reproduction, dental, mobility, ear, endocrinology and ruminants, grew roughly 12% excluding Thyronorm, the Indian thyroid-drug business it acquired in December 2025. "Achieving a solid +7.4% organic revenue growth to reach €768 million confirms our positive trajectory," said CEO Paul Martingell.
On the strength of the half, Virbac now targets the upper end of the 5.5% to 7.5% organic growth range it set in March, alongside an adjusted recurring operating margin of around 17% at constant rates. The base it is compounding from: €1,464.7 million in 2025 revenue, up 7.9% organically.
The divergence with Boehringer and Zoetis points at mix, not market
Five days before Virbac's release, Boehringer Ingelheim reported first-half animal health net sales of €2.6 billion, up just 0.4% currency-adjusted. Earlier this year, Zoetis posted flat Q1 revenue with US companion animal down 11%. Same market, same six months, three trajectories.
The difference is what each portfolio asks of the vet clinic. Parasiticides, vaccines and wellness-linked products ride visit volume; when owners stretch the interval between appointments, those franchises feel it immediately. Virbac's growth engines are condition-driven instead. Dental disease, ear infections, endocrine disorders and mobility problems get diagnosed once and then treated continuously, which makes the revenue recurring and far less sensitive to whether the annual wellness visit happens on schedule. When traffic softens, chronic-care categories keep compounding while traffic-linked categories flatten.
North America at 10.1% deserves its own note. Virbac is a €1.5 billion mid-cap next to giants, and double-digit US growth off a smaller base is easier to print. But the direction matters: the US vet channel is proving open to challenger portfolios in specialty categories at the same moment the majors are defending large, traffic-exposed franchises. For product companies, the read-through is to underwrite demand by category exposure rather than by overall pet-health beta. A margin target of 17% while growing 7% organically also says the specialty mix is carrying real pricing power, not just volume.
Zoetis reports in early August and will show whether this is share shift or category strength
Zoetis has scheduled its second-quarter call for early August, IDEXX reports August 4 with the diagnostics metrics that double as the best public proxy for US clinic traffic, and Freshpet follows August 5 on the nutrition side. If Zoetis' US companion animal book declines again while Virbac compounds at 10%, the read is share shift toward specialty challengers and chronic-care categories rather than a market-wide recovery. Three Virbac-specific items are worth tracking into year-end: whether North America holds double digits for a full year, whether the 17% margin target survives the currency drag that cut reported growth to 4%, and how Thyronorm contributes once it enters the organic base. A guidance nudge to the top of the range in July leaves room for one more raise, and mid-caps that deliver those tend to get re-rated.
Related Analysis
Other News
More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.
An Angel Network of Vets Backs a Platform That Pays the Clinic Before the Client Leaves
PawPay has become the newest portfolio company of the Veterinary Angel Network for Entrepreneurs on undisclosed terms. Acting as an authorized collection agent, the platform verifies coverage at checkout, collects only the owner's deductible and coinsurance, pays the clinic in full within minutes, and manages reimbursement with the carrier. It is free for practices to join and targets the direct-pay experience Trupanion has largely owned.
CVS's 9,000-Store Pet Meds Launch Comes for the Vet Pharmacy Margin
CVS Health switched on prescription pet medication dispensing at roughly 9,000 pharmacies nationwide, with app-based pet profiles and e-prescribing due within months. With human-generic pricing behind it, the highest-margin line in the vet clinic P&L just got a national competitor.
Purina's $644M Italy Plant Bets the Premium Fight on Wet Food, Not Fresh
Nestlé Purina confirmed a CHF 520 million ($644 million) superpremium wet pet food factory in Mantova, Italy, with production starting in 2029. The category leader is betting Europe's premium migration lands on shelf-stable wet rather than refrigerated fresh — and the three-year capacity gap before the plant opens is the operator opportunity.